Biomarkers of critical illness neuromyopathy after intensive care therapy - Development of early detection methods through the integration of clinical, immunological, and muscular diagnostics

Biomarkers of critical illness neuromyopathy after intensive care therapy - Development of early detection methods through the integration of clinical, immunological, and muscular diagnostics - CritMyo

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039651

Enrollment

Registered

2026-03-18

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical-Illness-Neuromyopathy (CINM) Intensive Care Unit Acquired Weakness U70.0

Interventions

Group 1: CINM risk group (N = 25): patients at risk of developing Critical-Illness-Neuromyopathy (CINM) following intensive care treatment (longer than 7 days) Group 2: Control group A (N = 25): patie

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: requirement for intensive care treatment, voluntary participation, written informed consent following appropriate information, sufficient German language proficiency

Exclusion criteria

Exclusion criteria: inability to provide informed consent (due to linguistic, psychological or somatic reasons), employees involved in the conduct of the study, pre-existing or suspected polyneuropathy or myopathy, prior immobilization; secondary: withdrawal of consent, if applicable by a previously designated representative, contraindications to specific study procedures (e.g. anticoagulation)

Design outcomes

Primary

Measure	Time frame
Prospective assessment of group differences in nerve and muscle morphology (ultrasonography) during the ICU stay, in association with group differences in symptoms of Critical-Illness-Neuromyopathy (CINM)	—

Secondary

Measure	Time frame
"• Assessment of group differences in muscle morphology (ultrasonography, histology), muscle function, and cytokine profiles in patients with Critical-Illness-Neuromyopathy (CINM) compared with both control groups (early and late phase of the ICU stay, as well as at follow-up) • Correlation of the different biomarkers with clinical symptoms and nerve-muscle morphology • Impact on quality of life and potential chronification"	—

Measure

Time frame

"• Assessment of group differences in muscle morphology (ultrasonography, histology), muscle function, and cytokine profiles in patients with Critical-Illness-Neuromyopathy (CINM) compared with both control groups (early and late phase of the ICU stay, as well as at follow-up) • Correlation of the different biomarkers with clinical symptoms and nerve-muscle morphology • Impact on quality of life and potential chronification"

—

Countries

Germany

Contacts

Public ContactClaudia Scheffzük

Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil Bochum

claudia.scheffzuek@ruhr-uni-bochum.de+49 234 302 6711

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026